Cat. No.: HY-B0203A

Nebivolol hydrochloride

(Synonyms: R 065824 hydrochloride)

6 Cited Publications

Customer Review

Based on 6 publication(s) in Google Scholar

Nebivolol (R 065824) hydrochloride is an orally active beta receptor blocker and has the high beta(1)-receptor affinity.Nebivolol hydrochloride has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol hydrochloride can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease.

For research use only. We do not sell to patients.

Purity: 99.94%
CAS No.: 152520-56-4
Formula: C₂₂H₂₆ClF₂NO₄
Molecular Weight:441.90

Storage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Nebivolol hydrochloride Chemical Structure

CAS No.: 152520-56-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- Clinical Trial
Chemical Information
Publications (6)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All Adrenergic Receptor Isoforms :

In Vitro

Nebivolol hydrochloride improves endothelial dysfunction via its strong stimulatory effects on the activity of the endothelial nitric oxide synthase and via its antioxidative properties^[1].
Nebivolol hydrochloride (0.1 μM-10 μM, 1, 2, 4, 7 or 14 days) inhibits haCSMC or haEC proliferation with IC₅₀ values of ~ 6.0 μM^[2].
Nebivolol hydrochloride (0.1 μM-10 μM, 24 h) induces a moderate rate of apoptosis^[2].
Nebivolol hydrochloride (0.1, 1, 5,10 μM, 4 days)increases NO formation and decreases endothelin-1 secretion in HaCEs^[2]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:

haCSMCs (human coronary smooth muscle cells) and haECs (endothelial cells)
Concentration:

0.1 μM-10 μM
Incubation Time:

1, 2, 4, 7 or 14 days
Result:

Reduced proliferation in HaECs and HaCSMCs in a concentration- and time-dependent.

Apoptosis Analysis^[2]

Cell Line:

haCSMCs and haECs
Concentration:

0.1 μM-10 μM
Incubation Time:

24 h
Result:

Induced a moderate apoptosis in concentration-dependent and showed a decrease of haCSMCs in the S-phase by 66%.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 152520-56-4
Appearance Solid
Molecular Weight 441.90
Formula C₂₂H₂₆ClF₂NO₄
Color White to off-white
SMILES

FC1=CC=C2C(CC[C@]([C@@H](O)CNC[C@H](O)[C@@]3([H])CCC(C=C(F)C=C4)=C4O3)([H])O2)=C1.Cl
Synonyms

R 065824 hydrochloride
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (6)

All Microbiological AssayWB

Sort by:

Journal Impact Factor

Nat Commun

Integrative residue-intuitive machine learning and MD Approach to Unveil Allosteric Site and Mechanism for β2AR. [Abstract]

2024 Sep 16;15(1):8130. PMID: 39285201
Free Radic Biol Med

Targeted delivery of nebivolol via lactoferrin-modified liposomes inhibits NEK7-mediated pyroptosis to ameliorate inflammatory bowel disease. [Abstract]

2026 Aug 16:252:493-508. PMID: 42061481
Br J Pharmacol

Therapeutic potential of small molecules that block receptor-induced Kv7/M-current suppression in neuroprotection, seizures, and pain. [Abstract]

2026 Jul;183(13):3780-3795. PMID: 41956525
PLoS Genet

Nebivolol suppresses glioblastoma progression via dual modulation of mitochondrial metabolism and AKT/mTOR/4EBP1 signaling axis. [Abstract]

2026 Apr 24;22(4):e1012120. PMID: 42030279
J Pharm Biomed Anal

Screening method of mildronate and over 300 doping agents by reversed-phase liquid chromatography-high resolution mass spectrometry. [Abstract]

2021 Feb 20:195:113870. PMID: 33453569
Virology

Structure-based virtual screening of ROCK1 inhibitors for the discovery of Enterovirus-A71 antivirals. [Abstract]

2023 Aug:585:205-214. PMID: 37384967

Nebivolol hydrochloride purchased from MedChemExpress. Usage Cited in: Virology. 2023 Aug:585:205-214. [Abstract]

RD cells were treated with the different concentrations (GSK269962A: 10 μM; Dasabuvir: 10 μM; Lumacaftor: 10 μM; Edoxaban: 10 μM; Nintedanib: 3 μM; Raltegravir: 10 μM; Nebivolol hydrochloride: 10 μM; Polydatin: 10 μM; Cabozantinib: 10 μM; Ezetimibe: 10 μM; Eltombopag: 2 μM; Leucovorin: 10 μM) of compounds were inoculated with EV-A71 at an MOI of 0.01 for 48 h. Viral titer was also determined for compounds-treated samples in TCID50 assays.

Nebivolol hydrochloride purchased from MedChemExpress. Usage Cited in: Virology. 2023 Aug:585:205-214. [Abstract]

RD cells were treated with the different concentrations (GSK269962A: 10 μM; Dasabuvir: 10 μM; Lumacaftor: 10 μM; Edoxaban: 10 μM; Nintedanib: 3 μM; Raltegravir: 10 μM; Nebivolol hydrochloride: 10 μM; Polydatin: 10 μM; Cabozantinib: 10 μM; Ezetimibe: 10 μM; Eltombopag: 2 μM; Leucovorin: 10 μM) of compounds were inoculated with EV-A71 at an MOI of 0.01 for 48 h. VP1 protein levels were detected using Western blot.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (226.30 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 1.79 mg/mL (4.05 mM; ultrasonic and warming and heat to 60°C)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2630 mL

11.3148 mL

22.6296 mL

5 mM

0.4526 mL

2.2630 mL

4.5259 mL

10 mM

0.2263 mL

1.1315 mL

2.2630 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Thomas Münzel, et al. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009 Oct 13;54(16):1491-9. [Content Brief]

[2]. Brehm BR, et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res. 2001 Feb 1;49(2):430-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	2.2630 mL	11.3148 mL	22.6296 mL	56.5739 mL
DMSO	5 mM	0.4526 mL	2.2630 mL	4.5259 mL	11.3148 mL
	10 mM	0.2263 mL	1.1315 mL	2.2630 mL	5.6574 mL
	15 mM	0.1509 mL	0.7543 mL	1.5086 mL	3.7716 mL
	20 mM	0.1131 mL	0.5657 mL	1.1315 mL	2.8287 mL
	25 mM	0.0905 mL	0.4526 mL	0.9052 mL	2.2630 mL
	30 mM	0.0754 mL	0.3772 mL	0.7543 mL	1.8858 mL
	40 mM	0.0566 mL	0.2829 mL	0.5657 mL	1.4143 mL
	50 mM	0.0453 mL	0.2263 mL	0.4526 mL	1.1315 mL
	60 mM	0.0377 mL	0.1886 mL	0.3772 mL	0.9429 mL
	80 mM	0.0283 mL	0.1414 mL	0.2829 mL	0.7072 mL
	100 mM	0.0226 mL	0.1131 mL	0.2263 mL	0.5657 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Nebivolol hydrochloride

6 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Nebivolol hydrochloride

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Infection Compound Library

GPCR/G Protein Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-COVID-19 Compound Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Neurodegenerative Disease-related Compound Library

Targeted Diversity Library

Rare Diseases Drug Library

Antidepressant Compound Library

FDA-Approved Anticancer Drug Library

Anti-Pulmonary Fibrosis Compound Library

Off-patent Drug Library

Antihypertensive Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Nebivolol hydrochloride

All Adrenergic Receptor Isoforms

Biological Activity

Chemical Information

Publications (6)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Nebivolol hydrochloride Related Classifications

HY-B0203A Related Classifications